
Gleamer raises €27m in Series B funding round
Gleamer SAS’ financing round was led by Supernova Invest, co-led by Heal Capital and backed by Gleamer’s long-term partners XAnge, Elaia, Bpifrance...

EG 427 expands Series A closing to €18m
EF 147, which got the additional €5m from undisclosed existing investors and new family office investors, is going to finance preclinical work upon...

Living therapy: Microbial immunotherapy of Exeliom Biosciences gets a boost
Exeliom Biosciences (Paris, France) is using its unique knowledge of the microbiome-immunomodulation axis to develop next-generation immunotherapies....

Fresh money for Carbios
In order to retain shareholders' preemptive subscription rights, French plastics recycling specialist Carbios SAS has announced the beginning of a...

Biomethane fuel offers negative carbon footprint
German scientists at the University of Hohenheim have reported that fuels made from agricultural residues can even have a negative CO2 impact on bus...

BioSenic halts ALLOB development
ALLOB was developed before the US$40.8m majority buyout of Bone Therapeutics by French Medsenic SAS last October. Before the reverse merger, in...

BioLamina AB bags €19m funding for expansion
The tenth investement from Lauxera Capital Partners through its Lauxera Growth I fund will be usesd by the Swedish company to expand the development...